Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK-based biopharmaceutical firm Lightlake Therapeutics has signed an agreement with a commercial contract manufacturer to start production of its opioid overdose reversal treatment, naloxone, an injectable medicine that can reverse the overdose of prescription and illicit opioids.
Subscribe to our email newsletter
Under the deal, the company expects that the ‘contract manufacturer’ will be able to offer sufficient manufacturing capacity at cGMP production facilities to allow commercialization of its treatment on a global scale.
The company has been developing a needleless intranasal delivery system for the delivery of naloxone that could widely expand the availability and use of the product in preventing opioid overdose deaths, a public health problem of epidemic proportion in the US.
Lightlake CEO Roger Crystal said, "We have been diligent in selecting our partner for the contract manufacturing process to best position us to produce a high quality treatment that can meet the requirements for FDA approval."
Lightlake CFO Kevin Pollack said the company is happy with the high quality of its partner involved in the contract manufacturing process.
"Our partner has the capacity to produce significant quantities of our intranasal naloxone spray at a reasonable cost, which could facilitate our scaling up production to address a growing population of potential users of our treatment and should save more lives," Pollack said.